Observational study in AIDS (London, England), 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
7 authors.
Alexis KayDivision of Infectious Diseases, Department of Medicine, University of California San Diego, San Diego, California.
Carlee MoserHarvard T.H. Chan School of Public Health, Boston, Massachusetts, USA.
Ashley McKhannHarvard T.H. Chan School of Public Health, Boston, Massachusetts, USA.
Milenka VargasDivision of Infectious Diseases, Department of Medicine, University of California San Diego, San Diego, California.
Magali PorrachiaDivision of Infectious Diseases, Department of Medicine, University of California San Diego, San Diego, California.
Sara GianellaDivision of Infectious Diseases, Department of Medicine, University of California San Diego, San Diego, California.
Martin HoeniglDivision of Infectious Diseases, Department of Medicine, University of California San Diego, San Diego, California.
Funding
Leadership and Operations Center (LOC), AIDS Clinical Trials Group (ACTG); LOC 1/UM1AI068636 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Joseph J Eron, RAJESH T GANDHI · 2011 to 2026
$1073.1M
Statistical and Data Management Center (SDMC), AIDS Clinical Trials Group (ACTG)UM1AI068634 · NIAID · HARVARD UNIVERSITY D/B/A HARVARD SCHOOL OF PUBLIC HEALTH · PI Marlene Ann Cooper, Michael David Hughes · 2011 to 2026
$246.6M
AIDS Clinical Trials Group NetworkU01AI068636 · NIAID · SOCIAL AND SCIENTIFIC SYSTEMS, INC. · PI KURITZKES, DANIEL R. · 2006 to 2010
$147.1M
Validation, CLIA and Qualification (VQC): Enhancing the RS ratio as a tool for AIDS Clinical Trial Group (ACTG) tuberculosis trialsUM1AI106701 · NIAID · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Grace M Aldrovandi · 2014 to 2026
$116.8M
Virology CoreP30AI027763 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI MALLORY O JOHNSON · 1988 to 2026
$93.6M
UC San Diego Clinical and Translational Research InstituteUL1TR001442 · NCATS · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI FIRESTEIN, GARY S, HOGARTH, MICHAEL · 2015 to 2024
$88.3M
VirologyP30AI036214 · NIAID · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI David Mitchell Smith · 1994 to 2026
$78.4M
Statistical and Data Management Center for the AIDS Clinical Trials GroupU01AI068634 · NIAID · HARVARD SCHOOL OF PUBLIC HEALTH · PI HUGHES, MICHAEL DAVID · 2006 to 2010
$71.9M
STRUCTURAL NEUROIMAGING COREP30MH062512 · NIMH · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI Jennifer E Iudicello · 2001 to 2026
$50.4M
Primary Infection Resource Consortium (PIRC)R24AI106039 · NIAID · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI LITTLE, SUSAN JANET · 2013 to 2021
$23.1M
Effect of Declining Sex Hormones on HIV persistence in HIV Infected Women on ARTR21HD094646 · NICHD · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI GIANELLA WEIBEL, SARA · 2017 to 2018
$441k
Perception of repeated negative HIV test results in young men who have sex with menR21MH113477 · NIMH · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI HOENIGL, MARTIN · 2018 to 2019
: Before initiation of antiretroviral therapy (ART), levels of soluble suppression of tumorigenicity 2 (sST2) were not elevated in people living with HIV who later developed non-AIDS events (including myocardial infarction and stroke), compared with controls. However, higher sST2 levels measured pre-ART were a significant predictor of death while on ART. Future studies should explore the potential of sST2 to serve as a short-term predictor of non-AIDS events during viral suppression.
Indexed as
DeathSustained Virologic ResponseAdultAgedAnti-Retroviral AgentsFemaleHIV InfectionsHumansInterleukin-1 Receptor-Like 1 ProteinLongitudinal StudiesMaleMiddle AgedPredictive Value of TestsSurvival AnalysisYoung AdultAnti-Retroviral AgentsIL1RL1 protein, humanInterleukin-1 Receptor-Like 1 Protein
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Soluble suppression of tumorigenicity 2 levels are not predictive of non-AIDS events during antiretroviral therapy-mediated viral suppression. · full record | OpenQuestion